 |
|
 |
US Preventive Services Task Force Calls For Chlamydia, Lipid Screening
In its first set of recommendations, the third U.S. Preventive Services Task Force (USPSTF) today recommended that primary care clinicians screen all sexually active women ages 25 and younger, as well as older women at risk for chlamydia, as part of regular health care visits. more |
|
Screening Adults for Lipid Disorders
This series of fact sheets is based on the work of the third U.S. Preventive Services Task Force (USPSTF). The USPSTF systematically reviews the evidence of effectiveness of a wide range of clinical preventive services--including screening, counseling, and chemoprevention (the use of medication to prevent diseases)--to develop recommendations for preventive care in the primary care setting. This fact sheet presents highlights of USPSTF recommendations on the topic of lipid screening and should not be used to make treatment or policy decisions. more |
|
|
|
Screening for Chlamydial Infection
This series of fact sheets is based on the work of the third U.S. Preventive Services Task Force (USPSTF). The USPSTF systematically reviews the evidence of effectiveness of a wide range of clinical preventive services--including screening, counseling, and chemoprevention (the use of medication to prevent diseases)--to develop recommendations for preventive care in the primary care setting. This fact sheet presents highlights of USPSTF recommendations on the topic of chlamydial screening and should not be used to make treatment or policy decisions. more |
|
Phase III Clinical Study Using Oral Chemotherapy Capecitabine For Metastatic Colorectal Cancer
The April 15 edition of the Journal of Clinical Oncology features Phase III clinical data about the use of Xeloda® (capaceitabine), an oral chemotherapy, in the first-line treatment of metastatic colorectal cancer, the second leading cause of cancer mortality among Americans. The US Food and Drug Administration is currently reviewing Xeloda as an oral chemotherapy for the treatment of colorectal cancer. more |
|
Prescribing Information: Xeloda (Capecitabine)
XELODA is indicated for the treatment of patients with metastatic breast cancer resistant to both paclitaxel and an anthracycline-containing chemotherapy regimen or resistant to paclitaxel and for whom further anthracycline therapy is not indicated, e.g. patients who have received cumulative doses of 400 mg/m2 of doxorubicin or doxorubicin equivalents. Resistance is defined as progressive disease while on treatment, with or without an initial response, or relapse within 6 months of completing treatment with an anthracycline-containing adjuvant regimen. more |
|
|
